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The labelling of pepsin-digested human glomerular basement membrane (pHGBM) with a newly developed 
fluorescent iodine acceptor 7-hydroxy-coumarin-3-acetic acid N-hydroxysucciniimydyl ester (CASE) is de- 
scribed. The binding of a monoclonal antibody to pHGBM was assessed by radiobinding assays, and when 
directly iodinated pHGBM was used there was no apparent binding. When CASE was conjugated to 
pHGBM prior to iodination 11% binding was achieved. CASE acting as an iodine acceptor may be useful 
for proteins containing few or inaccessible tyrosine residues or which are destroyed by introduction of lz51. 
Since CASE is fluorescent, small amounts of material can be detected during isolation prior to iodination. 
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1. INTRODUCTION 
Glomerular basement membrane is a complex 
extracellular matrix consisting of collagenous and 
noncollagenous components which can be 
solubilised by proteolytic digestion. Pepsin- 
digested human glomerular basement membrane 
(pHGBM) is a heterogenous mixture of proteins 
[l]. Studies using a monoclonal antibody MBM4, 
to characterise components of these digests, 
proved difficult because of the small amounts of 
material available. The incorporation of a 
radiolabel was therefore essential. In order that 
radiobinding assays could be performed, it was 
necessary to label the pHGBM fractions to a high 
specific activity, and iodine was chosen for this 
purpose. However, to our knowledge there are no 
reports on the successful iodine labelling of base- 
ment membranes as most studies report the label- 
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ling of purified proteins [2-41, the metabolic 
labelling of cells [5,6] or EHS tumour tissue [7]. 
Direct iodination of pHGBM resulted in very lit- 
tle incorporation of iodine into the MBMCbound 
component as shown by radiolabelling studies, 
even though the total iodine incorporation was 
often high. Attempts were therefore made to insert 
into the component a compound which could 
readily be iodinated but which would not affect its 
antigenicity. For this purpose, 7-hydroxy- 
coumarin-3-acetic acid-N-hydroxysucciniimidyl es- 
ter (CASE) proved to be particularly satisfactory. 
This compound has the added advantage that it is 
fluorescent and therefore allows detection and 
characterization of the antigen prior to iodination. 
2. EXPERIMENTAL 
Glomerular basement membrane (HGBM) was 
prepared from normal human kidneys obtained 
within 8 h of death. The cortex was dissected from 
the medulla, glomeruli prepared by sieving using a 
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modification of the method described by Spiro [8] 
and GBM isolated following sonication. Col- 
lagenous components were solubilised by digestion 
with pepsin (1 mg/lO mg GBM) in 0.5 M acetic 
acid at 10°C for 48 h 191. 
7-Hydroxy-coumarin-3-acetic acid was prepared 
by the method of Banerjee [IO]. The coumarin ac- 
tive ester, CASE, was prepared by reacting 
the 7-hydroxy-coumarin-3-acetic acid (233 mg, 
1 mmol) with dicyclohexylcarbodiimide (220 mg, 
1 mmol) and N-hydroxy-succiniimide (130 mg, 
1.18 mmol) in tetrahydrofuran (10 ml) at 4°C for 
16 h and then for 1 h at room temperature. The 
dicyclohexylurea formed was removed by filtration 
and the filtrate evaporated to dryness under 
vacuum. The residue was taken up into cold ethyl 
acetate (25 ml), filtered and the filtrate evaporated 
to dryness. The product was stored desiccated in 
the dark at 4°C. Prior to use CASE was dissolved 
(9 mg/ml) and diluted (1: 100) in 1,4-dioxan. 
Pepsin-digested GBM (pGBM) in acetic acid was 
adjusted to pH 8.3 with 3 M NaOH prior to label- 
ling with CASE. CASE (100~1) was added over 
30 min with continuous stirring and the reaction 
allowed to proceed for a further 30 min. Extensive 
dialysis against 0.01 M phosphate-buffered saline 
(pH 7.4) (PBS) was carried out at 4°C to remove 
excess unbound CASE. 
The CASE-labelled pHGBM and untreated 
pHGBM were fractionated on Sephadex G-75 
(fig.1) prior to iodination. Selected fractions (a) 
a 
h 
b 
and (b) were iodinated using IodogenTM reagent 
(Pierce and Warriner) as described by Salacinski et 
al. [ll] (fig.2). 
The iodinated proteins were then used as an- 
tigens in radiobinding assays. Dilutions of ‘251- 
antigens (50~1) were added to PBS/0.4% bovine 
serum albumin (50~1) and monoclonal antibody 
MBM4 (50~1, 1:20 dilution). The tubes were in- 
cubated at 37°C for 1 h and cooled on ice for 
5 min prior to addition of sheep anti-mouse serum 
(50~1, 1:22 dilution) and mouse serum (50~1, 
1 : 200 dilution). The tubes were further incubated 
at 37°C for 30 min and at 4°C overnight. The 
precipitates were washed twice by adding ice cold 
buffer (900 ~1). They were then centrifuged at 2000 
x g for 30 min, after which the radioactivity pre- 
sent in the precipitate was counted in a gamma 
counter. The radioactivity present in the 
precipitate was the amount of labelled antigen 
bound to excess MBM4 under the conditions 
stated. 
3. RESULTS 
Previous studies (unpublished) have indicated 
that MBM4 recognises a 350 kDa component in 
the pepsin-solubilised pHGBM fraction. Since this 
fraction is heterogeneous, gel filtration was per- 
formed in order to remove smaller proteins. The 
elution profile is shown in fig.1 and the CASE- 
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Fig.1. Fractionation of pHGBM on Sephadex G-75. The column (1 x 50 cm) was equilibrated and eluted with PBS. 
Fractions (1.5 ml) were collected at a flow rate of 45 ml/h. Fluorescence was measured at excitation and emission 
wavelengths of 365 and 455 nm, respectively, and protein absorbance at 280 nm. The fractions used for iodination are 
indicated by (a) and (b). 
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Fig.2. Iodination of coumarin-labelled protein. 
containing fractions (a) and (b) were selected for 
iodination. 
There was no binding to the antibody when 
directly labelled ‘251-pHGBM was used as antigen. 
This could be improved slightly by fractionating 
the pHGBM on a gel filtration column prior to 
iodination but the binding of peak (a) was still less 
than 1% and there was no binding of MBM4 to 
peak (b). However, there was a great increase in 
the percentage binding when r2%CASE-pHGBM 
was used as the antigen and binding between 
5-- 11% of peak (a) to MBM4 was achieved. Bind- 
ing of peak (b) remained lower, although that too 
was increased (0.3 to 2.4%). Some of the variation 
in the extent of labelled pHGBM bound to MBM4 
may be as a consequence of less antigen being pre- 
sent. This is governed by such factors as the 
sonication procedure and the extent of breakdown 
of the HGBM achieved during pepsin digestion. 
Introduction of CASE into pHGBM prior to 
iodination results in a greater capacity to accept 
iodine and typically 5%6.5% of the total 12’1 
would be incorporated into the protein using the 
iodogen method. 
4. DISCUSSION 
Tritium labelling of collagenous proteins has 
been used successfully for the analysis of proteins 
by SDS-polyacrylamide gel electrophoresis by 
several investigators [5,12]. However, high specific 
activity of labelled proteins is required for 
radiobinding assays and therefore, “‘1 labelling 
was essential. 
When direct labelling of pHGBM with iodine 
was attempted, insufficient label was incorporated 
into the antigen to distinguish binding of 12’1- 
pHGBM to MBM4 above background levels. Since 
pHGBM contains low levels of tyrosine residues 
[l] and some of these may be buried in the core of 
the a-helix (i.e., inaccessible for efficient iodina- 
tion), it is probable that this resulted in the low 
specific activity of the labelled material. When the 
low I%& non-antigenic components were removed 
by gel filtration a slight improvement in binding 
was observed, although it was still too low to be of 
practical value. The introduction of CASE as the 
iodine acceptor greatly increased the radioactivity 
present in the immune precipitates, which is direct- 
ly proportional to the extent of antigen binding. 
This is presumably because a more even distribu- 
tion of ‘25I molecules throughout the molecule was 
achieved. It is possible that direct iodine labelling 
destroyed the antigenicity of the protein, im- 
plicating a tyrosine residue(s) in the epitope. Since 
the 125 I is on a spacer arm in the CASE-conjugated 
protein such damage may have been prevented 
allowing recognition of the pHGBM by the an- 
tibody. CASE, like the Bolton and Hunter reagent 
[ 131 couples specifically to free amino groups 
under mild conditions and has the additional ad- 
vantage of being fluorescent. This latter property 
of CASE is very useful as it allows detection of 
proteins before iodination and small amounts of 
protein may be followed during a purification pro- 
cedure. The low fluorescence values recorded in 
this study are probably because of the small 
number of lysine residues in pepsin-digested base- 
187 
Volume 182, number 1 FEBS LETTERS March 1985 
ment membranes [14]. As CASE is a stable com- 
pound, the resulting CASE-protein conjugate can 
be stored at -20°C and aliquots iodinated as 
required. 
The novel approach to the iodination of the 
pHGBM described here might be of more general 
applicability to the labelling of proteins with a low 
number of oxidisable or clustered tyrosine 
residues. In a parallel study the conjugation of 
CASE to ovalbumin has been described [15]. 
CASE is easy to prepare, is stable when stored 
desiccated below 4°C and its fluorigenic property 
is useful in characterising the protein prior to 
iodination. This procedure should prove a valuable 
addition to the protein labelling methods currently 
available. 
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